HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From Bayer AG

US FDA Urged To Drop Snail Mail For IND Communications

Waiting for paper letters to arrive can delay drug development, companies contend, but moving completely to e-communication may be difficult for the FDA.

Research and Development Strategies FDA

Finance Watch: 2020 Cell And Gene Therapy Funding Already Bests 2019

Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.

Financing Innovation

Bayer Back In M&A Mode To Boost Pipeline

The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.

Deals Leadership

Is Disruption Just A Young Pup’s Game?

Big pharma has faced many evolutions to the pharma playbook of old. New technologies such as wearables introduce behavioral change to patients, while e-commerce giants such as Amazon seek a piece of the Rx action. The health care industry has done a reasonable job of weathering the storm inflicted on its core business model over the years, but it has yet to be a true disruptor. As the world marches on is pharma’s choice to disrupt, or inevitably be disrupted for good?

Business Strategies C-Suite Speaks
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Radiopharmaceuticals, Contrast Agents
  • Other Names / Subsidiaries
    • Algeta ASA
    • Bayer CropScience AG
    • Bayer Consumer Care AG
    • Berlex Laboratories
    • BlueRock Therapeutics
    • Conceptus Inc.
    • Dihon Pharmaceutical Group Co., Ltd.
    • Intendis GmbH
    • Jenapharm
    • Medrad Inc.
    • Possis Medical
    • Schering AG
    • Monsanto Company
    • Zeptosens AG
UsernamePublicRestriction

Register